Well its OK to hope, but belief without scientific proof is liable to lead to disappointment.
So far for indications such as heart failure and spinal disc healing the goal posts have shifted to post hoc analysis of surrogate end points and softer targets such "reduced GI bleeding" and "reduced back pain", and the number of patients in the trials required to show statistical significance has increased.
Evidence so far of efficacy is relatively weak and inconsistent, that's why the FDA is being cautious
MSB Trading 2020 - a new dawn, page-8368
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.32 |
Change
0.070(5.62%) |
Mkt cap ! $1.575B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.40 | $1.27 | $12.58M | 9.351M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 37572 | $1.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.32 | 9983 | 2 |
View Market Depth
| Last trade - 13.28pm 03/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |